Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.
CHRYSOPHAENTIN ANTIMICROBIAL COMPOUNDS THAT INHIBIT FTSZ PROTEIN
申请人:The United States of America, as represented by
The Secretary, Department of Health and Human
Services
公开号:EP2539305B1
公开(公告)日:2017-02-15
US8399689B2
申请人:——
公开号:US8399689B2
公开(公告)日:2013-03-19
US9169182B2
申请人:——
公开号:US9169182B2
公开(公告)日:2015-10-27
[EN] CHRYSOPHAENTIN ANTIMICROBIAL COMPOUNDS THAT INHIBIT FTSZ PROTEIN<br/>[FR] COMPOSÉS ANTIMICROBIENS DE CHRYSOPHANÉINE INHIBANT LA PROTÉINE FTSZ
申请人:US HEALTH
公开号:WO2011106630A2
公开(公告)日:2011-09-01
Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, and methods for using the chrysophaentin compounds are disclosed. Some embodiments of the disclosed compounds are isolated from Chrysophaeum taylori. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.